TREM2 promotes the proliferation and invasion of renal cell carcinoma cells by inhibiting the P53 signaling pathway

Zhang,Liang; Lv,Zhong; Xu,Qin-Yu; Wu,Bin

doi:10.3892/ol.2024.14671

TREM2 promotes the proliferation and invasion of renal cell carcinoma cells by inhibiting the P53 signaling pathway

Authors:
- Liang Zhang
- Zhong Lv
- Qin-Yu Xu
- Bin Wu
View Affiliations

Affiliations: Department of Urology, Wujin Hospital Affiliated with Jiangsu University, Changzhou, Jiangsu 213003, P.R. China
Published online on: September 6, 2024 https://doi.org/10.3892/ol.2024.14671
Article Number: 538
Copyright: © Zhang et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Renal cell carcinoma (RCC) is a prevalent malignancy characterized by poor prognosis and high mortality. The role of triggering receptor expressed on myeloid cells‑2 (TREM2) in RCC progression has been increasingly recognized, yet its underlying mechanisms remain to be fully elucidated. The aim of the present study was to assess the effects of TREM2 on RCC cells and its potential mechanisms. Lentiviral transfection was used to knockdown and overexpress TREM2 in RCC cells, and the expression level of TREM2 was evaluated using reverse transcription‑quantitative PCR. Cell Counting Kit‑8 (CCK‑8) and 5‑ethynyl‑2'‑deoxyuridine (EdU) assays were used to assess the proliferation of the RCC cells. Cell migration and invasion was evaluated using the wound healing assay and Transwell assay, respectively. Western blotting was used to assess the expression levels of TREM2, P53, p‑P53, P21 and p‑P21 in TREM2 knockdown or overexpression RCC cells. The results demonstrated that the expression level of TREM2 was significantly higher in cancer tissues compared with adjacent normal tissues. The results of the CCK‑8 and EdU assays demonstrated that knockdown of TREM2 significantly inhibited the proliferation of RCC cells, whilst overexpression of TREM2 enhanced the proliferation of RCC cells. The results of the wound healing and Transwell assay revealed that, compared with the control group, the overexpression of TREM2 significantly increased the migration and invasion of RCC cells, whereas knockdown of TREM2 significantly decreased the migration of RCC cells. In addition, western blotting demonstrated that the phosphorylation levels of P53 and P21 proteins were significantly increased after TREM2 knockdown in RCC cells. In conclusion, TREM2 is highly expressed in RCC tissues and promotes the migration of RCC cells by inhibiting the P53 signaling pathway. The present study provides new insights into the regulatory effect of TREM2 on RCC and further reveals the potential of TREM2 as a therapeutic target for RCC.

View Figures

View References

1	Miller KD, Nogueira L, Devasia T, Mariotto AB, Yabroff KR, Jemal A, Kramer J and Siegel RL: Cancer treatment and survivorship statistics, 2022. CA Cancer J Clin. 72:409–436. 2022. View Article : Google Scholar : PubMed/NCBI
2	Linehan WM and Ricketts CJ: The cancer genome atlas of renal cell carcinoma: Findings and clinical implications. Nat Rev Urol. 16:539–552. 2019. View Article : Google Scholar : PubMed/NCBI
3	Campi R, Rebez G, Klatte T, Roussel E, Ouizad I, Ingels A, Pavan N, Kara O, Erdem S, Bertolo R, et al: Effect of smoking, hypertension and lifestyle factors on kidney cancer-perspectives for prevention and screening programmes. Nat Rev Urol. 20:669–681. 2023. View Article : Google Scholar : PubMed/NCBI
4	Ge W, Song S, Qi X, Chen F, Che X, Sun Y, Wang J, Li X, Liu N, Wang Q and Wu G: Review and prospect of immune checkpoint blockade therapy represented by PD-1/PD-L1 in the treatment of clear cell renal cell carcinoma. Oncol Res. 31:255–270. 2023. View Article : Google Scholar : PubMed/NCBI
5	Harrison H, Thompson RE, Lin Z, Rossi SH, Stewart GD, Griffin SJ and Usher-Smith JA: Risk prediction models for kidney cancer: A systematic review. Eur Urol Focus. 7:1380–1390. 2021. View Article : Google Scholar : PubMed/NCBI
6	Joerger AC and Fersht AR: Structural biology of the tumor suppressor p53. Annu Rev Biochem. 77:557–582. 2008. View Article : Google Scholar : PubMed/NCBI
7	Wu D and Prives C: Relevance of the p53-MDM2 axis to aging. Cell Death Differ. 25:169–179. 2018. View Article : Google Scholar : PubMed/NCBI
8	Zavileyskiy L and Bunik V: Regulation of p53 function by formation of non-nuclear heterologous protein complexes. Biomolecules. 12:3272022. View Article : Google Scholar : PubMed/NCBI
9	Wang H, Guo M, Wei H and Chen Y: Targeting p53 pathways: Mechanisms, structures, and advances in therapy. Signal Transduct Target Ther. 8:922023. View Article : Google Scholar : PubMed/NCBI
10	Chen JX, Xu D, Cao JW, Zuo L, Han ZT, Tian YJ, Chu CM, Zhou W, Pan XW and Cui XG: TRIM47 promotes malignant progression of renal cell carcinoma by degrading P53 through ubiquitination. Cancer Cell Int. 21:1292021. View Article : Google Scholar : PubMed/NCBI
11	Jian W, Xue W, Wang T, Yu Y, Cai L, Meng Y, Xia Z and Zhang C: RBM4 inhibits the growth of clear cell renal cell carcinoma by enhancing the stability of p53 mRNA. Mol Carcinog. 62:464–478. 2023. View Article : Google Scholar : PubMed/NCBI
12	Fassler M, Benaim C and George J: TREM2 agonism with a monoclonal antibody attenuates tau pathology and neurodegeneration. Cells. 12:15492023. View Article : Google Scholar : PubMed/NCBI
13	Molgora M, Liu YA, Colonna M and Cella M: TREM2: A new player in the tumor microenvironment. Semin Immunol. 67:1017392023. View Article : Google Scholar : PubMed/NCBI
14	Li RY, Qin Q, Yang HC, Wang YY, Mi YX, Yin YS, Wang M, Yu CJ and Tang Y: TREM2 in the pathogenesis of AD: A lipid metabolism regulator and potential metabolic therapeutic target. Mol Neurodegener. 17:402022. View Article : Google Scholar : PubMed/NCBI
15	Katzenelenbogen Y, Sheban F, Yalin A, Yofe I, Svetlichnyy D, Jaitin DA, Bornstein C, Moshe A, Keren-Shaul H, Cohen M, et al: Coupled scRNA-Seq and intracellular protein activity reveal an immunosuppressive role of TREM2 in cancer. Cell. 182:872–885.e19. 2020. View Article : Google Scholar : PubMed/NCBI
16	Park MD, Reyes-Torres I, LeBerichel J, Hamon P, LaMarche NM, Hegde S, Belabed M, Troncoso L, Grout JA, Magen A, et al: TREM2 macrophages drive NK cell paucity and dysfunction in lung cancer. Nat Immunol. 24:792–801. 2023. View Article : Google Scholar : PubMed/NCBI
17	Zhang H, Sheng L, Tao J, Chen R, Li Y, Sun Z and Qian W: Depletion of the triggering receptor expressed on myeloid cells 2 inhibits progression of renal cell carcinoma via regulating related protein expression and PTEN-PI3K/Akt pathway. Int J Oncol. 49:2498–2506. 2016. View Article : Google Scholar : PubMed/NCBI
18	Amin MB, Edge SB, Greene FL, Byrd DR, Brookland RK, Washington MK, Gershenwald JE, Compton CC, Hess KR, Sullivan DC, et al: AJCC cancer staging manual. 8th edition. New York: Springer; 2017
19	World Medical Association, . World medical association declaration of Helsinki: Ethical principles for medical research involving human subjects. JAMA. 310:2191–2194. 2013. View Article : Google Scholar : PubMed/NCBI
20	Livak KJ and Schmittgen TD: Analysis of relative gene expression data using real-time quantitative PCR and the 2(−Delta Delta C(T)) method. Methods. 25:402–408. 2001. View Article : Google Scholar : PubMed/NCBI
21	Salic A and Mitchison TJ: A chemical method for fast and sensitive detection of DNA synthesis in vivo. Proc Natl Acad Sci USA. 105:2415–2420. 2008. View Article : Google Scholar : PubMed/NCBI
22	Liang CC, Park AY and Guan JL: In vitro scratch assay: A convenient and inexpensive method for analysis of cell migration in vitro. Nat Protoc. 2:329–333. 2007. View Article : Google Scholar : PubMed/NCBI
23	Leber MF and Efferth T: Molecular principles of cancer invasion and metastasis (review). Int J Oncol. 34:881–895. 2009.PubMed/NCBI
24	Li C, Hou X, Yuan S, Zhang Y, Yuan W, Liu X, Li J, Wang Y, Guan Q and Zhou Y: High expression of TREM2 promotes EMT via the PI3K/AKT pathway in gastric cancer: Bioinformatics analysis and experimental verification. J Cancer. 12:3277–3290. 2021. View Article : Google Scholar : PubMed/NCBI
25	Wang J and Li Z: TREM2 is a prognostic biomarker and correlated with an immunosuppressive microenvironment in thyroid cancer. Dis Markers. 2022:18073862022. View Article : Google Scholar : PubMed/NCBI
26	Hanahan D and Weinberg RA: Hallmarks of cancer: The next generation. Cell. 144:646–674. 2011. View Article : Google Scholar : PubMed/NCBI
27	Jung Y, Kraikivski P, Shafiekhani S, Terhune SS and Dash RK: Crosstalk between Plk1 and p53, cell cycle, and G2/M DNA damage checkpoint regulation in cancer: Computational modeling and analysis. NPJ Syst Biol Appl. 7:462021. View Article : Google Scholar : PubMed/NCBI
28	Saha T, Solomon J, Samson AO and Gil-Henn H: Invasion and metastasis as a central hallmark of breast cancer. J Clin Med. 10:34982021. View Article : Google Scholar : PubMed/NCBI
29	Kim SM, Kim EM, Ji KY, Lee HY, Yee SM, Woo SM, Yi JW, Yun CH, Choi H and Kang HS: TREM2 Acts as a tumor suppressor in colorectal carcinoma through Wnt1/β-catenin and Erk signaling. Cancers (Basel). 11:13152019. View Article : Google Scholar : PubMed/NCBI
30	Tang W, Lv B, Yang B, Chen Y, Yuan F, Ma L, Chen S, Zhang S and Xia J: TREM2 acts as a tumor suppressor in hepatocellular carcinoma by targeting the PI3K/Akt/β-catenin pathway. Oncogenesis. 8:92019. View Article : Google Scholar : PubMed/NCBI
31	Engeland K: Cell cycle regulation: p53-p21-RB signaling. Cell Death Differ. 29:946–960. 2022. View Article : Google Scholar : PubMed/NCBI
32	Liu J, Peng Y and Wei W: Cell cycle on the crossroad of tumorigenesis and cancer therapy. Trends Cell Biol. 32:30–44. 2022. View Article : Google Scholar : PubMed/NCBI
33	Sabapathy K and Lane DP: Corrigendum to ‘understanding p53 functions through p53 antibodies’. J Mol Cell Biol. 11:11052019. View Article : Google Scholar : PubMed/NCBI
34	Hernández Borrero LJ and El-Deiry WS: Tumor suppressor p53: Biology, signaling pathways, and therapeutic targeting. Biochim Biophys Acta Rev Cancer. 1876:1885562021. View Article : Google Scholar : PubMed/NCBI
35	Chen L, Liu S and Tao Y: Regulating tumor suppressor genes: Post-translational modifications. Signal Transduct Target Ther. 5:902020. View Article : Google Scholar : PubMed/NCBI
36	Shamloo B and Usluer S: p21 in cancer research. Cancers (Basel). 11:11782019. View Article : Google Scholar : PubMed/NCBI
37	Lei X, Gou YN, Hao JY and Huang XJ: Mechanisms of TREM2 mediated immunosuppression and regulation of cancer progression. Front Oncol. 14:13757292024. View Article : Google Scholar : PubMed/NCBI
38	Tan J, Fan W, Liu T, Zhu B, Liu Y, Wang S, Wu J, Liu J, Zou F, Wei J, et al: TREM2⁺ macrophages suppress CD8⁺ T-cell infiltration after transarterial chemoembolisation in hepatocellular carcinoma. J Hepatol. 79:126–140. 2023. View Article : Google Scholar : PubMed/NCBI
39	Sun R, Han R, McCornack C, Khan S, Tabor GT, Chen Y, Hou J, Jiang H, Schoch KM, Mao DD, et al: TREM2 inhibition triggers antitumor cell activity of myeloid cells in glioblastoma. Sci Adv. 9:eade35592023. View Article : Google Scholar : PubMed/NCBI